Trial reportThorax2026
Loop gain predicts residual sleep apnoea among people using positive airway pressure.
Trial report in Thorax, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rethinking Long-Term Follow-Up of CPAP Therapy in Obstructive Sleep Apnea: Toward Personalized and Integrated Care.Healthcare (Basel, Switzerland) · 2026Review
- Article
- The upper airway in obstructive sleep apnoea: state of the art.European respiratory review : an official journal of the European Respiratory Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
rationaleResidual sleep apnoea-defined by an Apnoea-Hypopnoea Index ≥10 events/hour-affects~20% of obstructive sleep apnoea patients treated with positive airway pressure therapy and poses a major clinical challenge. Ventilatory control instability is a plausible cause of residual sleep apnoea. Elevated loop gain (LG), a measure of ventilatory instability, may be a risk factor, but this has not been rigorously tested.
objectiveTo assess whether high LG at baseline is associated with residual sleep apnoea on positive airway pressure therapy in two large, randomised control trials: Apnoea Positive Pressure Long-Term Efficacy Study (APPLES) and Randomised Intervention with CPAP in Coronary Artery Disease and OSA (RICCADSA).
methodsLG was estimated from baseline polysomnography using a validated method. Residual sleep apnoea was defined using polysomnography on positive airway pressure at 2 months (APPLES) or device downloads at 3 months (RICCADSA). Logistic regression estimated the odds of residual sleep apnoea with high LG (highest quartile), adjusting for confounders. A sensitivity analysis was performed using linear regression, where both the exposure and outcome were defined continuously. MEASUREMENTS AND MAIN
resultsIn the unadjusted analysis, high LG was associated with threefold odds of residual sleep apnoea in both samples. After adjustment, elevated odds persisted in both APPLES (2.17 (1.24-3.78)) and RICCADSA (3.31 (1.33-8.24)). Associations remained after accounting for measures of central sleep apnoea. Linear regression confirmed the association of LG and residual Apnoea-Hypopnoea Index.
conclusionsHigh LG is a significant risk factor for residual sleep apnoea on positive airway pressure therapy. Ventilatory control instability identified at baseline may warrant closer monitoring or the initiation of adjunctive therapies aimed at reducing LG and improving the therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.